Equillium Results Presentation Deck

Bench to Bedside: The CD6-ALCAM Pathway In Lupus Nephritis Pre-clinical Blockade of CD6 shown to be efficacious in multiple pre-clinical models of SLE/LN1 Translational Antigen specific, autoreactive CD6+ T cells key to SLE/LN pathogenesis² Single cell RNAseq data of LN kidneys versus normal showed a: 16x increase in infiltrating CD6+ T cells 9x increase in ALCAM expression on renal tissues¹ Urinary ALCAM a biomarker of active disease³ Clinical Exploratory analysis of SLE patients in Type A portion of the EQUALISE study, with elevated UPCR & UACR, showed an improvement with treatment4 equillium MRL/1pr: % Survival 100- Urine ALCAM (pg/mg) 50- Ln (normalized expression) 0- H 10 20000 KEpithelial Control isotype anti-mCD6 cyclophos. MMF naive (MPJ) 15 Active LN CD6 K.Epithelial SLE K.Leukocyte Control 20 Age (Weeks) K.Leukocyte SLE U.Leukocyte.SLE Active Non Renal 25 K.Epithelial Control ALCAM 打南部 K.Epithelial. SLE K.Leukocyte.Control Inactive SLE **** KLeukocyte.SLE ** 17.5. 30 U.Leukocyte SLE Healthy Control JCI 2022 Vol 132 jolarg The Journal of Clinical Investigation Contribution of CD6/ALCAM interactions in lupus nephritis nature REVIEWS NEPHROLOGY UPCR, urine protein creatinine ratio: UACR, urine albumin creatinine ratio 1. Chalmers et al., Journal of Clinical Investigation, 2022: 2. Abdirama et al., Clinical Investigation, 2021; 3. Parodis et al., Rheumatology, 2020; 4. Putterman et al., PO1624 ASN, 2021 12

View entire presentation